Stock Analysis on Net
Stock Analysis on Net

Stryker Corp. (NYSE:SYK)

This company has been moved to the archive! The financial data has not been updated since April 29, 2022.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Stryker Corp., EBITDA calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net earnings 1,994 1,599 2,083 3,553 1,020
Add: Income tax expense 287 355 479 (1,197) 1,043
Earnings before tax (EBT) 2,281 1,954 2,562 2,356 2,063
Add: Interest expense 337 315 287 264 247
Earnings before interest and tax (EBIT) 2,618 2,269 2,849 2,620 2,310
Add: Depreciation 371 340 314 306 271
Add: Amortization of intangible assets 619 472 464 417 371
Earnings before interest, tax, depreciation and amortization (EBITDA) 3,608 3,081 3,627 3,343 2,952

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The financial performance between 2017 and 2021 is characterized by a general upward trajectory in operational profitability, interrupted by a notable contraction in 2020 followed by a strong recovery in 2021. Earnings before interest, tax, depreciation and amortization (EBITDA) served as a primary indicator of this trend, growing consistently from US$ 2,952 million in 2017 to a peak of US$ 3,627 million in 2019.

EBITDA Growth and Recovery Patterns
A positive growth trend is evident from 2017 through 2019, with EBITDA increasing by approximately 22.8% over this period. A significant decline occurred in 2020, where EBITDA fell to US$ 3,081 million, representing a 15% decrease from the previous year. However, a robust recovery was observed in 2021, as the figure rose to US$ 3,608 million, nearly returning to the 2019 peak and indicating a restoration of operational cash flow generation.
Analysis of Depreciation and Amortization
The gap between EBITDA and Earnings before interest and tax (EBIT) has expanded consistently every year from 2017 to 2021. In 2017, the difference was US$ 642 million, which grew to US$ 990 million by 2021. This steady increase in depreciation and amortization expenses suggests a continuous investment in fixed assets or intangible acquisitions, indicating an expansion of the company's long-term asset base.
Earnings Volatility and Net Income Divergence
While operational metrics like EBITDA and EBIT remained relatively stable, net earnings exhibited significant volatility. A substantial spike is noted in 2018, where net earnings reached US$ 3,553 million, far exceeding the EBIT and EBT for that year, which suggests the impact of non-operating gains or one-time tax benefits. Subsequent years show a normalization of net earnings, which fluctuated between US$ 1,599 million and US$ 2,083 million, trailing the operational EBITDA trend more closely.
Operating Margin Resilience
The relationship between EBIT and EBT indicates a gradual increase in interest or non-operating expenses over the five-year period. The difference between these two metrics rose from US$ 247 million in 2017 to US$ 337 million in 2021. Despite these increasing costs, the ability of the organization to rebound its EBITDA in 2021 demonstrates operational resilience in the face of the 2020 downturn.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Enterprise Value to EBITDA Ratio, Current

Stryker Corp., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 100,693
Earnings before interest, tax, depreciation and amortization (EBITDA) 3,608
Valuation Ratio
EV/EBITDA 27.91
Benchmarks
EV/EBITDA, Competitors1
Abbott Laboratories 14.36
Elevance Health Inc. 8.27
Intuitive Surgical Inc. 33.26
Medtronic PLC 13.24
UnitedHealth Group Inc. 16.92
EV/EBITDA, Sector
Health Care Equipment & Services 14.65
EV/EBITDA, Industry
Health Care 19.75

Based on: 10-K (reporting date: 2021-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

Stryker Corp., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 104,469 103,264 88,412 73,519 59,894
Earnings before interest, tax, depreciation and amortization (EBITDA)2 3,608 3,081 3,627 3,343 2,952
Valuation Ratio
EV/EBITDA3 28.95 33.52 24.38 21.99 20.29
Benchmarks
EV/EBITDA, Competitors4
Abbott Laboratories 17.42 — — — —
Elevance Health Inc. 10.05 — — — —
Intuitive Surgical Inc. 44.10 — — — —
Medtronic PLC 24.41 — — — —
UnitedHealth Group Inc. 17.39 — — — —
EV/EBITDA, Sector
Health Care Equipment & Services 18.05 — — — —
EV/EBITDA, Industry
Health Care 14.33 — — — —

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 See details »

2 See details »

3 2021 Calculation
EV/EBITDA = EV ÷ EBITDA
= 104,469 ÷ 3,608 = 28.95

4 Click competitor name to see calculations.


The financial trajectory between 2017 and 2021 is characterized by a significant expansion in enterprise valuation alongside fluctuating operational earnings, resulting in an overall increase in the valuation multiple.

Enterprise Value Trends
A consistent upward trajectory in enterprise value is observed, rising from US$ 59,894 million in 2017 to US$ 104,469 million by 2021. This represents a substantial increase in the total market valuation over the five-year period.
EBITDA Performance
Earnings before interest, tax, depreciation, and amortization grew steadily from 2017 to 2019, reaching US$ 3,627 million. A notable contraction occurred in 2020, where EBITDA decreased to US$ 3,081 million, before recovering to US$ 3,608 million in 2021.
EV/EBITDA Ratio Analysis
The EV/EBITDA ratio experienced a sustained increase from 20.29 in 2017 to a peak of 33.52 in 2020. This expansion was driven by the simultaneous rise in enterprise value and the decline in EBITDA during 2020, suggesting a period of higher valuation relative to earnings. In 2021, the ratio contracted to 28.95, reflecting the recovery of operational earnings relative to the growth in enterprise value.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?